CompletedNot applicableNCT02100930

Anti-GD2 3F8 Monoclonal Antibody and GM-CSF for High-Risk Neuroblastoma

Studying Neuroblastoma

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Memorial Sloan Kettering Cancer Center
Principal Investigator
Brian Kushner, MD
Memorial Sloan Kettering Cancer Center
Intervention
Anti-GD2 3F8 Monoclonal Antibody(biological)
Enrollment
69 enrolled
Eligibility
All sexes
Timeline
2014 – 2019

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02100930 on ClinicalTrials.gov

Other trials for Neuroblastoma

Additional recruiting or active studies for the same condition.

See all trials for Neuroblastoma →

← Back to all trials